【摘要】 目的　探讨癌症患者血浆中尿激酶型纤溶酶原激活物 (u -PA )及其受体 (u -PAR )检测的临床意义。方法　采用ELISA法测定 85例癌症患者血浆中u -PA和u -PAR水平 ,并与正常人进行比较。结果　肝癌、肺癌、大肠癌、胰腺癌和胃癌患者的血浆u -PA和u -PAR水平均同步升高 ,与对照组比较有显著性差异 (P <0 .0 5或P <0 .0 1) ;胃癌和肺癌患者u -PA和u -PAR水平在术后出现明显回落 (P <0 .0 5或P <0 .0 1) ,复发时又升高 ;胰腺癌有转移者明显高于无转移者 (P <0 .0 5 ) ;鼻咽癌仅有u -PAR水平高于对照组 (P <0 .0 1)。结论　癌症患者血浆u -PA和u -PAR水平显著异常 ,可作为评估浸润转移和复发的参考指标更多还原

【Abstract】 Objective To explore clinical significance and levels of plasma urokinase type plasminogen activator(u PA) and its receptor(u PAR) in cancer.Methods The levels of plasma u PA and u PAR were measured by ELISA in 85 patients with cancer,and compared with healthy subjects.Results The levels of plasma u PA and u PAR in gastric,lung,pancreatic,hepatic and colorectal cancer were significantly higher than in normal control( P <0.01).In gastric and lung cancer,these two parameters in postoperation group were significantly lower than in preoperation group ( P <0.01),and they were risen again when cancer recurred.They in metastasized group of pancreatic carcinoma were markedly elevated compared with nonmetastasized group( P <0.05).In nasopharynx cancer,only the u PAR level was significantly increased.Conclusion The levels of plasma u PA and u PAR are markedly abnormal in cancer,may be as useful indicators to metastasize and recurrence.更多还原